Role of angiotensin receptor blockers in the treatment of chronic heart failure: What do the clinical practice guidelines say?;Papel de los ARA-II en el tratamiento de la insuficiencia cardiaca: ¿Qué dicen las guías de práctica clínica?

Revista Espanola de Cardiologia Suplementos

Volumn 6, Issue C, 2006, Pages

  Cleland, John G F ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Angiotensin receptor blockers; Evidence based medicine; Guidelines; Heart failure; Randomised controlled trials

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; ENALAPRIL; LISINOPRIL; LOSARTAN; PLACEBO; SPIRONOLACTONE; VALSARTAN;

CLINICAL STUDY; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT;

EID: 34848922169     PISSN: 11313587     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al; Task Froce for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J. 2005;26:1115-40.
2. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis Gs, Ganiats, TG, et al, American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005; 112:e154-235.
3. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al; on behalf of the ELITE study group. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the elderly study, ELITE). Lancet. 1997;349:747-52.
4. Pitt B, Poole Wilson PA, Segal R, Martínez FA, Dickstein K, Camm AJ, et al; on behalf of the ELITE II investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial -the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-7.
5. McKelvie RS, Yusuf S, Pericak D, Math M, Avezum A, Burns RJ, et al. Comparison of Candesartan, Enalapril and their combination in congestive heart failure. Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) Pilot Study. Circulation. 1999;100:1056-64.
6. Cohn JN, Tognoni G; for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-75.
7. Cohn JN, Tognoni G, Glazer RD, Spormann D. Baseline demographics of the valsartan heart failure trial. Eur J Heart Failure. 2000;2:439-46.
8. Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, et al; for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-6.
9. McMurray J, Ostergren J, Pfeffer M, Swedberg K, Granger C, Yusuf S, et al; on behalf of the CHARM committees and investigators. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Failure. 2003;5:261-70.
10. McMurray JJV, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al; for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-71.
11. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, et al; for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure; the CHARM-Overall programme. Lancet. 2003;362:759-66.
12. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, et al; for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:771-81.
13. Yusuf S, Ostergren J, Gerstein HC, Pfeffer MA, Swedberg K, Granger C, et al; on behalf of the Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity Program (CHARM) Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation. 2005;112:53.
14. Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJV, et al. Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients. The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Program. Circulation. 2004;110:2180-3.
15. O'Meara E, Solomon S, McMurray J, Pfeffer M, Yusuf S, Michelson E, et al. Effect of candesartan on New York Heart Association functional class. Eur Heart J. 2004;25:1920-6.
16. O'Meara E, Lewis E, Granger C, Dunlap ME, McKelvie RS, Probstfield JL, et al. Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure; Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail. 2005;7:650-6.
17. Maggioni AP, Opasich C, Anand I, Barlera S, Carbonieri E, Gonzini L, et al. Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. J Card Fail. 2005;11:91-8.
18. Anand I, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A, et al; for the Val-HeFT Investigators. Anemia and Change in Hemoglobin Over Time Related to Mortality and Morbidity in Patients With Chronic Heart Failure. Results From Val-HeFT. Circulation. 2005;112:1121-7.
19. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, et al; for the Val-HeFT Investigators. C-Reactive Protein in Heart Failure. Prognostic Value and the Effect of Valsartan. Circulation. 2005;112:1428-34.
20. Baruch L, Glazer RD, Aknay N, Vanhaecke J, Heywood JT, Anand I, et al. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2004;148:951-7.
21. Krum H, Carson P, Farsang C, Maggioni AP, Glazer RD, Aknay N, et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail. 2004;6:937-45.
22. Majani G, Giardini A, Opasich C, Glazer RD, Hester A, Tognoni G, et al. Effect of Valsartan on Quality of Life When Added to Usual Therapy for Heart Failure: Results From The Valsartan Heart Failure Trial. J Card Fail. 2005;11:253-9.
23. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer RD, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149:548-57.
24. Demers C, McMurray JJ, Swedberg K, Pfeffer MA, Granger CB, Olofsson B, et al. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA. 2005;294:1794-8.
25. Sharma D, Buyse M, Pitt B, Rucinska EJ; the losartan heart failure morbidity meta-analysis study group. Meta-analysis of observed mortality data from all controlled, double-blind multiple-dose studies of losartan in heart failure. Am J Cardiol. 2000;85:187-92.
26. Erdmann E, George M, Voet B, Belcher G, Kolb D, Hiemstra S, et al. The safety and tolerability of candesartan cilexetil in CHF. JRAAS. 2000;1:S31-6.
27. Dickstein K, Kjekshus J; the OPTIMAAL steering committee for the OPTIMAAL study group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet. 2002;360:752-60.
28. Dickstein K, Kjekshus J; for the OPTIMAAL Trial Steering Committee and Investigators. Comparison of Baseline Data, Initial Course and Management: Losartan versus Captopril Following Acute Myocardial Infarction (The OPTIMAAL Trial). Am J Cardiol. 2001;87:766-71.
29. Pfeffer MA, McMurray JJV, Velázquez EJ, Rouleau JL, Kober L, Maggioni AP, et al; for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-906.
30. Velázquez EJ, Pfeffer MA, McMurray JJV, Maggioni AP, Rouleau JL, Van De Werf F, et al. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. Eur J Heart Fail. 2003;5:537-44.
31. Young JB, Dunlap ME, Pfeffer MA, Probstfield CL, Cohen-Solal A, Dietz R, et al, Candesartan in Heart failure of Reduction in Mortality and morbidity (CHARM) Investigators and Committees. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004;110:2618-26.
32. Cleland JGF, Clark AL. Delivering the cumulative benefits of triple therapy for heart failure. Too many cooks will spoil the broth. J Am Coll Cardiol. 2003;42:1226-33.
33. Packer M, Poole Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD, Massie B, et al; on behalf of the ATLAS investigators. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100:2312-8.
34. The NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J. 1998;19:481-9.
35. Cleland JGF, Poole Wilson PA. ACE inhibitors for heart failure: a question of dose. Br Heart J. 1994;72:106-10.
36. Matsumori A. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail. 2003;5:669-77.
37. Carson P, Tognoni G, Cohn JN. Effect of valsartan on hospitalization: results from Val-HeFT. J Card Fail. 2003;9:164-71.
38. Pfeffer MA, McMurray JJ, Velázquez EJ, Rouleau JL, Kober L, Maggioni AP, et al; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-906.
39. Cleland JGF, Freemantle N, Kaye GC, Nasir M, Velavan P, Lalukota K, et al. Clinical trials update from the American Heart Association: omega-3 fatty acids and arrhythmia risk in patients with implantable defibrillators, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORBIT and PAD and DEFINITE. Eur J Heart Failure. 2004;6:109-15.
40. Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al; for the Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure Survey Programme: Survey on the Quality of Care Among Patients with Heart Failure in Europe. Part 1: Patient Characteristics and Diagnosis. Eur Heart J. 2003;24:422-63.
41. Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G, et al; for the CHARM-Programme Investigators. Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and Design. J Card Fail. 1999;5:276-82.
42. Anónimo. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New Engl J Med. 1991;325:293-302.
43. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, et al. Emerging role of angiotensin converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994;90:2056-69.
44. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. New Engl J Med. 2000;342:145-53.
45. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-8.
46. Coletta AP, Cleland JG, Freemantle N, Loh H, Memon A, Clark AL. Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM. Eur J Heart Failure. 2003;5:697-704.
47. Cleland JGF, Tendera M, Adamus J, Freemantle N, Gray CS, Lye M, O'Mahony, et al; on behalf of the PEP-CHF investigators. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. Eur J Heart Fail. 1999;1:211-7.
48. Banerjee P, Banerjee T, Khand A, Clark AL, Cleland JGF. Diastolic heart failure - neglected or misdiagnosed? J Am Coll Cardiol. 2002;39:138-41.
49. Anand IS, Fisher LD, Chiang Y-T, Latini R, Masson S, Maggioni AP, et al; for the Val-HeFT Investigators. Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107:1278-83.
50. Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang Y-T, et al; for the Val-HeFT Investigators. Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2002;106:2454-8.
51. Maggioni A, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN; for the Valsartan Heart Failure Trial Investigators. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin converting enzyme inhibitors. J Am Coll Cardiol. 2002;40:1414-21.
52. Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang Y-T, et al. Valsartan Benefits Left Ventricular Structure and Function in Heart Failure: Val-HeFT Echocardiographic Study. J Am Coll Cardiol. 2002;40:970-5.
53. Cohn JN, Tognoni G, Glazer RD, Spormann D, Hester A. Rationale and design of the valsartan heart failure trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail. 1999;5:155-60.